CYAD-211 is an allogeneic (donor) CAR T Cell therapy that targets the B-cell maturation antigen (BCMA) chimeric antigen receptor.
SparkCures ID | 389 |
---|---|
Developed By | Celyad Therapeutics |
Generic Name | CYAD-211 |
Treatment Classifications | |
Treatment Targets |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
June 11, 2021
Safety and tolerability data:
Of the six patients dosed at the first two dose levels (30×106 and 100×106 cells per infusion):
Clinical activity:
Of the five evaluable patients at the first two dose levels (30×106 and 100×106 cells per infusion):
Cell kinetics:
Next steps:
January 22, 2021